BioCentury | Jun 26, 2020
Distillery Therapeutics

Promoting Golgi fragmentation to treat pancreatic cancer

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inducing Golgi complex fragmentation by inhibiting the transcription factor KLF7 or the Golgi integrity maintenance factors DLG3 or STX5 could treat pancreatic ductal adenocarcinoma (PDAC). In pancreas samples from...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Jul 13, 2018
Clinical News

FDA lifts hold on Aptose blood cancer candidate

Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) said FDA lifted a two-and-a-half year clinical hold on a Phase Ib trial evaluating IV APTO-253 in patients with hematologic malignancies. In 2015, FDA placed a hold on the open-label,...
BioCentury | May 24, 2018
Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

A Nankai University-based team developed a small circular single-stranded DNA molecule that inhibits cancer growth in cells and mice by sequestering microRNAs (miRNAs) that silence tumor suppressor genes. Preclinical deals in nucleic acid modalities over...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Feb 3, 2017
Clinical News

APTO-253: Development delayed

Aptose said it will “temporarily delay clinical activities” for its IV APTO-253 to allow the company to investigate the cause of manufacturing issues. Aptose said it will prioritize its resources on preclinical cancer candidate CG026806...
BioCentury | Oct 27, 2016
Distillery Therapeutics

Neurology

...INDICATION: Cognitive dysfunction Mouse studies suggest transiently promoting KLF9 expression could help treat age-related memory impairment...
...the effects of sustained or continuous KLF9 expression on memory in the aged mice. TARGET/MARKER/PATHWAY: Kruppel-like factor 9 (KLF9)...
...2016 doi:10.1016/j.neuron.2016.08.009 CONTACT: Amar Sahay, Massachusetts General Hospital , Boston, Mass. email: asahay@mgh.harvard.edu Steven Hochhauser Massachusetts General Hospital Kruppel-like factor 9 (KLF9)...
BioCentury | Oct 24, 2016
Clinical News

APTO-253: Phase Ib hold

Aptose said it received a response from FDA regarding a clinical hold the agency placed last November on its open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. According to Aptose,...
BioCentury | Sep 19, 2016
Clinical News

APTO-253: Phase Ib hold

Aptose said it submitted a formal response to FDA’s requests following a November 2015 clinical hold on an open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. The company had voluntarily...
BioCentury | Apr 7, 2016
Distillery Therapeutics

Therapeutics: MAP kinase kinase kinase kinase 3 (MAP4K3; GLK); kruppel-like factor 2 (KLF2); kruppel-like factor 4 (KLF4; EZF)

Cardiovascular disease INDICATION: Cardiovascular Patient sample and mouse studies suggest inhibiting the MAP4K3- KLF2 / KLF4 pathway could help treat cerebral cavernous malformations (CCMs), which involve the formation of highly dilated blood vessels and symptoms...
Items per page:
1 - 10 of 54